Revive’s Quarterly Report, Discussion, and a Video!
With 5,000 hospitalizations reported daily (150,000 a month), contracting Covid is not something to be taken lightly - after you get it.
Unless of...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found in Virtually all...
Cybin (CYBN) and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s...
- Preliminary data confirm Flow's ability to successfully measure neuro-effect of ketamine over 10 days -
- Results to be presented at PSYCH Symposium taking...
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
As we stated earlier, Revive Therapeutics (RVVTF)...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...
Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...
New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
Early Bird Gets the Worm?
Here's...
Revive Therapeutics (RVVTF, RVV): Updates and News Archive.
Recent Headlines
(See FDA Filing Submission at Bottom)
LIVE QUOTE
NEWS ARCHIVE INTRO
“These medicines have a sweet spot. If the day you get diagnosed with COVID you...
Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs
IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs
TORONTO, Jan. 17, 2022 (GLOBE...
Ehave’s Mobile Ketamine Clinic, Rolling into Town.
Longer term, Ehave's (EHVVF) performance has been a quite a disappointment. Investors grew impatient for the launch of one of the most significant advances...
The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21.
Revive Therapeutics (RVTTF), RedHill BioPharma (RDHL), AI Pharma (Private), Apilli Thera...
Latest article
GeoVax (GOVX) Surges 51% on Massive Volume Spike.
MonkeyPox and Gedeptin Related News Spark New Investor Interest.
MARKET BRIEF
On a quiet Thursday afternoon, the 30th, while we were nearing completion of an updated...
Paving Past Obstacles on the Path to US Biosecurity
GeoVax’s CEO calls on government support to bolster domestic biotechnology and keep pace with China.
National biosecurity has become a frequent topic of conversation in...
Dinner Presentation With BioStem Technologies, Inc. (BSEM) in Boca Raton, FL
LIVE QUOTE
LONGER TERM CHART
Contact Ray Oliver at Bear Creek Capital for details.
RECENT NEWS
PRESENTATION
https://youtu.be/Au-pIqDHyto?si=_JKFAhwT-vvLSFqe
WOUND CARE REPORT
Global Wound Care Market to Reach USD 30.48 Billion by...
